Clinical Roundup Mutation predicts chemoresistance and better responses to immunotherapy in advanced bladder cancer, MD Anderson study finds January 16, 2026Vol.52 No.02
Clinical Roundup Mayo develops AI tool that predicts prostate cancer recurrence January 16, 2026Vol.52 No.02
Clinical Roundup LSU researchers identify proteins linked to prostate cancer January 16, 2026Vol.52 No.02
Drugs & Targets FDA accepts NDA for pimicotinib for treatment of tenosynovial giant cell tumor January 16, 2026Vol.52 No.02
Drugs & Targets City of Hope, Cellares collaborate to automate manufacturing of solid tumor CAR T-cell therapy January 16, 2026Vol.52 No.02
Drugs & Targets Verana Health and COTA merge to accelerate research-ready oncology real-world evidence January 16, 2026Vol.52 No.02
Drugs & Targets UAMS Winthrop P. Rockefeller Cancer Institute expands OnCore to strengthen clinical trials January 16, 2026Vol.52 No.02
A planned randomized trial will ask an intriguing question: Do COVID vaccines potentiate checkpoint inhibitors? January 09, 2026Vol.52 No.1By Sara Willa Ernst and Jacquelyn Cobb
Trials & Tribulations How a Montefiore Einstein screening program is changing the history of lung cancer in the Bronx January 09, 2026Vol.52 No.1By Brendon M. Stiles
Cancer Policy NIH agrees to review hundreds of denied or shelved grant applications January 09, 2026Vol.52 No.1By Claire Marie Porter
